ライフサイエンスコーパス: mean weight

1 ts and an effective way to reduce population mean weight.

2 Of the hamsters with small tumors (mean weight 0.43 +/- 0.25 g), 87.5% were disease-free 7

3 When hamsters with larger tumors (mean weight 0.66 +/- 0.11 g) were treated with 64Cu- or

4 Based on the increase in snake mackerel (mean weight 0.8 kg) and lancetfish catches, the discards

5 7 patients received platinum segment chains (mean weight, 1.2 +/- 0.2 g; range, 0.8-1.6 g) for lagoph

6 Eight hundred juvenile shrimp (Initial mean weight: 1.54 +/- 0.04 g) were randomly allocated in

7 = 670; mean age, 48 years; 473 [71%] women; mean weight, 107.3 kg) who completed the 36-week lead-in

8 allograft recipients weighing < or = 15 kg, mean weight 11.2 +/- 2.6 kg.

9 e 585 men (mean [SD] age, 50.7 [13.3] years; mean weight, 118.5 [19.9] kg; mean BMI, 37.7 [5.7]; 525

10 nor age less than 5 years vs. 6 to 10 years (mean weight, 16.4 vs. 32.7 kg) revealed no differences i

11 We enrolled 13,478 (52.2% male, mean weight: 2,575.0 grams standard deviation [SD] 521.0

12 eviation [SD] 521.0) and 13,109 (52.0% male, mean weight: 2,607.0 grams SD 509.0) newborn infants in

13 Domestic Yorkshire pigs (n = 4; mean weight, 23.4 kg) were anesthetized, and their liver

14 ult anesthesized and paralyzed mongrel dogs (mean weight 24.3+/- 4.4 kg).

15 Ten healthy swine (mean weight, 24.6 kg) with saline lavage-induced acute l

16 Six anesthetized, paralyzed mongrel dogs (mean weight, 24.7+/-3.8 kg).

17 F0145 (10 to 40 mg) in 13 closed chest dogs (mean weight 25.6 kg).

18 Nineteen healthy swine (mean weight 28.9 kg) with saline lavage-induced acute lu

19 wenty-eight infants (mean age 1 +/- .6 days, mean weight 3.6 +/- .6 kg) with critical aortic stenosis

20 Thirty-two piglets (mean weight, 30 [range, 24-35] kg).

21 Thirty-two mixed-breed piglets (mean weight, 30 kg).

22 placed in the livers of seven domestic pigs (mean weight, 30.0 kg +/- 14.0 [SD]) as tumor-mimicking l

23 Twenty adult female sheep (mean weight, 33.1+/-0.9 kg).

24 .9+/-5.8 years (range, 29 days to 18 years), mean weight 37.2+/-27.5 kg (range, 1.7-149.1 kg).

25 was retrospectively validated in six swine (mean weight, 37.3 kg +/- 7.5 [standard deviation]) betwe

26 Twelve healthy growing swine (mean weight, 38.4 kg; weight range, 30.3-47.0 kg) were e

27 balance in 12 boys and 13 girls aged 9-14 y (mean weight: 42 kg) maintained on relatively high calciu

28 embolization were tested in three farm pigs (mean weight 43 kg +/- 2 [standard deviation]) under real

29 Results Eleven swine (10 male; mean weight, 43.6 kg +/- 2.6 [SD]) were evaluated with 7

30 ablation was performed in 18 domestic pigs (mean weight, 45 kg) by using a 17-gauge (1.5-mm-diameter

31 Thirteen female domestic pigs (mean weight, 45 kg) were used.

32 thoracotomy in eight female domestic swine (mean weight, 55 kg) by using a microwave ablation system

33 lemented to sheep (Charolais x Suffolk-Mule (mean weight = 57 +/- 2.9 kg) at two European industrial

34 Two hundred forty shrimp (mean weight 6.0 +/- 0.02 g) were randomly assigned to fo

35 ositive PTH gradient, a parathyroid adenoma (mean weight 636 +/- 196 mg) was resected from a location

36 for 7 minutes at 60 W in six porcine livers (mean weight, 68.2 kg) by using single (n = 7) or dual 2.

37 The non-commercial species lancetfish (mean weight 7 kg) has now surpassed the target species,

38 Thirteen female domestic swine (mean weight, 70 kg) were used for the study as approved

39 Mean weight (78 +/- 19 vs 67 +/- 16 kg), body mass index

40 dard deviation]; age range, 52.8-67.4 years; mean weight, 78.9 kg +/- 18.3; 12 men, 10 women) gave in

41 and four men; mean age 27.4 years [SD 6.2], mean weight 79.6 kg [SD 12.7], mean height 174.7 cm [SD

42 e, 56.1 years +/- 15.8 [standard deviation]; mean weight, 79.1 kg +/- 14.8) who underwent routine CT

43 age +/- SD, 37.2 +/- 15.6 y; range, 28-65 y; mean weight, 79.2 +/- 21.0 kg; range, 64-115 kg) were in

44 om donors less than or equal to 10 kg (n=11; mean weight=8.85 kg), but there was a higher incidence o

45 ino; high viral load; advanced fibrosis; and mean weight, 82 kg) were 28.4%, 24.3%, 20.6%, and 21.4%

46 ected parathyroid glands were hypercellular (mean weight = 895 +/- 86 mg).

47 Two groups of 5 piglets (mean weight 9.6+/-1.3 kg) with a cranial window over par

48 g 9 months, 45 patients (mean age, 44 years; mean weight, 92.5 kg) prospectively underwent both nonen

49 was 8.28%, the mean age 56.6 years, and the mean weight 93.7 kg.

50 omen (mean age, 28.1 years; Hispanic, 81.6%; mean weight above prepregnancy weight, 7.8 kg; mean mont

51 is of covariance methods were used to obtain mean weight and body fat changes adjusted for potential

52 Mean weight and length of the children did not significa

53 4) and control (n = 1185) groups had similar mean weights and BMIs.

54 recipient sex, race, cause of renal failure, mean weight, and follow-up duration (37.8 vs. 37.5 month

55 The unadjusted mean weight at 12 months declined from 102.7 kg to 99.8

56 Median age was 38 years, 85% were male, mean weight at baseline was 73 kg.

57 loss during initiation was 7.2 kg (SD, 3.1); mean weight at randomization was 103.6 kg (SD, 20.4).

58 Mean weight at the time of transplantation was 3.8+/-1.0

59 The mean weight at transplantation was 31.5 +/- 16.5 kg (ran

60 group lost almost 3 kg over 12 months (crude mean weight: baseline 104.38 kg [SD 21.11; n=279], 6 mon

61 Mean weight/body mass index unit loss after revision of

62 Mean weight change (primary outcome) was -0.61% (95% con

63 Mean weight change at 12 months was -5.06 kg (SE 0.31) f

64 In the entire study population, mean weight change at 12 months was 2.43 kg with the sup

65 There was no evidence of differences in mean weight change comparing bad and neutral news, and n

66 greater weight gain than the control group (mean weight change difference, 1.6 kg; 95% CI, -1.5 to 4

67 Mean weight change following referral was - 0.69 kg (SD

68 st weight; after 6 months, the least-squares mean weight change for those taking paliperidone palmita

69 Mean weight change from baseline in the intervention gro

70 Mean weight change from baseline to 5 years was -0.46 (S

71 The mean weight change from baseline was -15.8% with semaglu

72 weight at 12 months (difference in adjusted mean weight change from baseline: -0.07 [95% CI 1.7 to -

73 Mean weight change in the control group at the same time

74 ntinuing TAF was associated with an adjusted mean weight change of -0.54 kg (95% confidence interval

75 n weight change at 12 months by group with a mean weight change of -1.2 kg (95% CI, -2.1 to -0.3 kg)

76 The mean weight change over each of the 4-y follow-up cycles

77 At 18 months, the mean weight change was -1.9 kg (95% CI, -2.8 to -1.0 kg)

78 During the VLCD/LCD period, the pooled mean weight change was -12.3 kg (median duration: 8 wk;

79 Mean weight changes among children who achieved nonoverw

80 At 1 year, mean weight changes in the groups were -3.26 kg (brief i

81 Mean weight changes were small in the 25-, 50-, and 75-m

82 switching from TAF to TDF led to an adjusted mean weight decrease of -1.84 kg (95% CI -2.72 to -.97),

83 CS and FS treatments significantly increased mean weight diameter (MWD) and fractal dimension (D) in

84 tent of soil aggregates > 0.25 mm (R(0.25)), mean weight diameter and geometric mean diameter were si

85 The main outcome was the mean weighted difference of % change in HbA(1c) after at

86 HbA(1c) level at 12 months follow-up, with a mean weighted difference of 0.5% (95% CI 0.31-0.68) in t

87 rTMS versus sham treatment for AVH yielded a mean weighted effect size of .44.

88 with a frequency of 1 Hz yielded a moderate mean weighted effect size of .63, indicating superiority

89 patients with medication-resistant AVH, the mean weighted effect size was .45.

90 No significant mean weighted effect size was found for the severity of

91 a meta-analysis to establish and compare the mean weighted effect sizes (WESs) of the 4 most commonly

92 Standardized mean weighted effect sizes were computed; a qualitative

93 The overall mean weighted effect was significant (Hedges g, 0.67; 95

94 The overall summary mean weighted estimates of sensitivity and specificity w

95 Our top-performing model achieved a mean weighted F1 score of 96.86% on the validation set a

96 Physicochemical parameters (mean weight, firmness, dry matter, soluble solids conten

97 Mean weighted follow-up duration was 7.4 years (in 13 st

98 Mean weighted follow-up time across trials was 2.3 years

99 n the autistic cases differed from normative mean weight for age by a mean of 17.6% (95% CI, 10.2%-25

100 88, 95% CI 0.71-1.08), and the difference in mean weight-for-age Z score was 0.09 (95% CI -0.04 to 0.

101 d (1035 vs. 835 cells/mm(3); P=.043), higher mean weight-for-age Z scores (-0.15 vs. -0.84; P=.01), a

102 Mean weight-for-age z scores were marginally higher in t

103 19 prepubertal girls aged 6.0-10.1 y with a mean weight-for-height of 108% of ideal.

104 The primary outcome was mean weight-for-height or -length z-score (WHZ) at 2-mon

105 the course of treatment (P < 0.003), higher mean weight-for-height z score at discharge (P < 0.008),

106 Infants in the RP group also had lower mean weight-for-length percentiles at 1 year than infant

107 , male 5alphaR1-KO mice demonstrated greater mean weight gain (21.6 +/- 1.4 vs 16.2 +/- 2.4 g), hyper

108 The mean weight gain among discharged children was 2.7 +/- 1

109 ng women with BMI<30 prior to the pregnancy, mean weight gain decreased with increasing months of lac

110 Mean weight gain from 0-48 weeks was 3.6 kg (SD 7.3); 13

111 Mean weight gain from baseline to 12 months was 1.8 kg (

112 near regression models were used to estimate mean weight gain in 14 y of follow-up according to each

113 Age-adjusted models showed a lower mean weight gain in participants who increased their caf

114 Mean weight gain in the LT patients was 1.0 kg versus 2.

115 ally, 35% of the participants gained weight (mean weight gain in these individuals, 1.8 kg SD 1.3 kg)

116 0.01), whereas among obese women (BMI>/=30), mean weight gain increased with increasing duration of l

117 group was 1.13 kg (SD 4.12), compared with a mean weight gain of 0.51 kg (3.65) in the control group,

118 A mean weight gain of 1.5 kg was observed with saroglitaza

119 Mean weight gain over 4-year intervals among participant

120 The mean weight gain over 96 weeks was 2.90 (95% confidence

121 The differences in postpartum mean weight gain persisted over the 8-year study period.

122 The mean weight gain velocity from admission to discharge wa

123 The mean weight gain was 1.4 kg (95% confidence interval [CI

124 The mean weight gain was higher in the prandial group than i

125 Mean weight gain was higher with deflation than inflatio

126 Mean weight gain was substantial (7.1 kg [SD 7.4] in the

127 ith those receiving mildly hypotonic fluids (mean weight gain, 279 vs 195 g; 95% CI, 16-154 g; P = .0

128 Overall, lactation was not associated with mean weight gain.

129 ong those with high acute insulin secretion, mean weight-gain rate was still rather low in those with

130 For these 40 patients, the mean weight gained at year 1 did not regress by the end

131 smoking to quit-smoking in a given year had mean weight gains of 2.95 kg/year (3.61%) in men and 3.0

132 year were 5.7, 12.0, and 2.3; and respective mean weight gains were 4.7 kg, 5.7 kg, and 1.9 kg.

133 h quetiapine-ER (p=0.0008), with an adjusted mean weight group difference at week 12 of 3.33 kg (SD 7

134 At 3 years after the procedure, the mean weight had decreased by 27% (95% confidence interva

135 Mean weights in inferior retina were 9% (M), 50% (S), an

136 omerizations per rod per second (Rh*/rod/s), mean weights in superior retina were 52% (M), 2% (S), an

137 Participants who switched to TAF had a mean weight increase of +0.5 kg at 144 weeks over those

138 The mean weight increase was 5.5 kg; half was attributable t

139 Relative to placebo, mean weight increased by 1.2 kg with 2 g EPA (95% CI, 0

140 e 1-year follow-up (2006-2007 to 2007-2008), mean weight increased by 1.72 kg (standard deviation, 4.

141 years of follow-up (1996-1997 to 1999-2000), mean weight increased by 2.1 kg (standard deviation (SD)

142 Mean weight increases of 2.2 kg. and 0.9 kg occurred in

143 Cronbach alpha values for mean weighted internal consistency were 0.83 and 0.89 fo

144 mphysema in each lobe showed good agreement (mean weighted kappa = 0.70) and correlated with findings

145 high level of intrarater reliability, with a mean weighted kappa value of 0.81 (95% confidence interv

146 The mean weighted kappa values in 2006 were 0.36 (range 0.21

147 us, preplus, or normal) among the 6 experts (mean weighted kappa, 0.27; range, 0.06-0.63), but good c

148 The mean-weighted LA thrombus prevalence was 2.73% (95% conf

149 The mean weighted LDL-C gene score of the WHII participants

150 ative UK patients had a significantly higher mean weighted LDL-C score (1.0 [SD 0.21]) than did WHII

151 Mean weight, length, and head circumference of children,

152 After 3 wk, the mean weight loss (5.12 +/- 1.83 kg) was induced in all d

153 body mass index decreased post-operatively (mean weight loss 59 +/- 15 kg, pre-operative body mass i

154 t to lifestyle intervention, lead to greater mean weight loss and an increased likelihood of achievin

155 terventionists, were associated with greater mean weight loss and likelihood of patients losing 5% or

156 By study exit, mean weight loss and mean HbA1c% reduction were 15.4 +/-

157 Mean weight loss at 24 months was -4.4 kg (95% CI, -5.5

158 Mean weight loss at baseline was 18% (n = 518).

159 e per-protocol analysis of 253 participants, mean weight loss at the end of the initial 3-month inter

160 y <=1.2 kg, whereas diet adherence increased mean weight loss by 1.1, 1.8, and 0.3 kg, respectively.

161 ications to lifestyle intervention increases mean weight loss by 2.5 to 8.9 kg compared with placebo.

162 At week 64, the mean weight loss compared with baseline was -10.1 kg (95

163 Although mean weight loss did not reach the targeted 5%, the mean

164 ing tube placement in 35 patients (85%), the mean weight loss during chemoradiotherapy was 13.3% of i

165 Mean weight loss during initiation was 7.2 kg (SD, 3.1);

166 Mean weight loss for diet + exercise participants was 10

167 ta-analysis of orlistat, the estimate of the mean weight loss for orlistat-treated patients was 2.89

168 The mean weight loss for topiramate-treated subjects who com

169 ing data, RYGB participants had the greatest mean weight loss from baseline (27.0%; 95% CI, 30.8-23.3

170 At 24 months, mean weight loss in the intervention and control groups

171 Mean weight loss in the intervention group was 1.13 kg (

172 completed the 20-week run-in period (with a mean weight loss of 10.6%) and were randomized (mean age

173 et, without exercise training, resulted in a mean weight loss of 13 kg and a body mass index (in kg/m

174 t-stimulated hormone-based therapies, induce mean weight loss of 15% or more.

175 Lifestyle interventions can lead to a mean weight loss of 2% to 9% of initial weight at 1 year

176 e, tirzepatide has the greatest effect, with mean weight loss of 21% at 72 weeks.

177 Treatment was associated with mean weight loss of 5.0 kg (95% CI 3.5,6.5 kg), mean HbA

178 The women in the intervention group had a mean weight loss of 8.0% (7.8 kg), as compared with 1.6%

179 The zonisamide group (n = 19) had a mean weight loss of 9.2 kg (1.7 kg) (9.4% loss) at week

180 and 50.1 kg/m2 to 211 lbs and 34 kg/m2 for a mean weight loss of 97 lbs and mean excess weight loss o

181 aseline BMI was 29.5 kg/m2 (SD 5.1), and the mean weight loss prior to baseline assessments was 11.4

182 ion duration range: 6-72 mo (median: 24 mo), mean weight loss range: 1%-9%] were included.

183 posed to 4% acetic acid solution exhibited a mean weight loss rate (WLR) for the control group (Dicor

184 After the masked treatment phase ended, the mean weight loss relative to baseline that was maintaine

185 dults, the use of SBWI resulted in a greater mean weight loss than STEP over 18 months.

186 After the 16-wk LED-only period, the mean weight loss was -15.0 kg (95% CI: -16.6, -13.4 kg),

187 In intention-to-treat analyses, the mean weight loss was 4.4 kg in the intervention group an

188 At 48 weeks, estimated mean weight loss was 5.7 kg (95% CI, 4.3 to 7.0 kg) in t

189 At 12 months, mean weight loss was 6.0% of initial weight in the inter

190 t analysis with baseline value substitution, mean weight loss was 7.4 kg (95% confidence interval [CI

191 During the initial 6-month program, mean weight loss was 8.5 kg.

192 Clinically meaningful superior mean weight loss was achieved when access to AOMs was pr

193 Mean weight loss was significantly (P < .001) greater in

194 P showed equivalent and clinically impactful mean weight loss with cardiometabolic benefits.

195 gnificantly by intervention group (estimated mean weight loss, 3.5 kg [95% CI, 2.6-4.5} in the enhanc

196 0 eligible participants (mean age, 52 years; mean weight loss, 8.3 kg) provided a fecal sample that w

197 Secondary outcomes were mean weight loss, percentage of patients achieving 5% or

198 At 6 months, the mean weight loss, relative to baseline, in the HF-F2F an

199 the amylin analog pramlintide elicited 12.7% mean weight loss, significantly more than was observed w

200 ot randomly assigned to this group (n = 294; mean weight loss: 0.8 kg).

201 rmal-weight, energy-balanced state (phase 4; mean weight loss: 12.9 +/- 2.0 kg).

202 ed to the weight-loss intervention (n = 291; mean weight loss: 4.4 kg) did not differ significantly f

203 Mean weight losses were 3.0 lb (1.36 kg) and 0.1 lb (0.0

204 with < or = 25% maximal cytoreduction had a mean weighted median survival time of 22.7 months, where

205 orts with <= 25% maximal cytoreduction had a mean weighted median survival time of 22.7 months, where

206 th more than 75% maximal cytoreduction had a mean weighted median survival time of 33.9 months--an in

207 th more than 75% maximal cytoreduction had a mean weighted median survival time of 33.9 months-an inc

208 adrenalectomy specimens was 28-297 g, with a mean weight of 122 g.

209 ared in neonatal (approximately 11 days old, mean weight of 24.5 g, mean volume of 25 cm3) and adult

210 had dilation at a mean age of 13 days and a mean weight of 3.4 kg.

211 5 cm3) and adult (approximately 80 days old, mean weight of 373.5 g, mean volume of 346 cm3) male Spr

212 For a patient population with a mean weight of 92 kg and no history of severe liver dise

213 Mean weight of each defecation and stool moisture did no

214 portion of females, mean prosomal width, and mean weight of L. polyphemus were also observed.

215 with either FGR (2 standard deviations below mean weight of nonchallenged dams) or normal weight.

216 After 4 weeks of treatment, the mean weight of primary tumors in animals receiving AN-23

217 The mean weight of the cohort reduced by 29.2% from 149.0 +/

218 The mean weight of the mice was 24 g (SD = 2 g), with ages r

219 Mean weights of fed ticks and percentage reaching replet

220 Mean weights of ingredients were calculated to obtain th

221 ant differences were found between groups in mean weight or body mass index-for-age z scores, waist c

222 Mean weighted overall percentages of NODM after DP for d

223 significantly older (P = .015), had a lower mean weight (P = .019), lower 25 hydroxy-vitamin D level

224 The mean weight percentile at closure was greater and the de

225 tnatal growth and development with a current mean weight percentile of 62+/-37 (median 80).

226 y significant increases from baseline in the mean weight percentiles were observed at years 1, 2, and

227 The mean weighted pretest probabilities of deep myometrial i

228 of catch and effort data for 23 species with mean weights ranging from 0.8 kg to 224 kg, recorded by

229 The overall mean weight reduction from week 0 to 88 was 25.3% for ti

230 ted the 36-week lead-in period experienced a mean weight reduction of 20.9%.

231 (1.0) in the control group, and a sustained mean weight reduction of 7.5 kg (SE 0.4) versus an incre

232 At 24 months, mean weight regain (+/- SE) was 2.1 +/- 0.62 kg and 4.9

233 Primary outcome was mean weight regain at week 56.

234 weight loss in the first 24 weeks, absolute mean weight regain from 24 to 48 weeks was +2.9 kg (CI 1

235 Estimated mean weight regain was statistically significantly lower

236 beta coefficients, that is, the mean weight regain, compared with the reference, and 95%

237 lar between groups except for differences in mean weight (SD) (81 [17.3] vs. 76.3 [15.6]) and cumulat

238 Twelve swine (mean weight +/- SD, 38 +/- 5 kg) underwent percutaneous

239 nd significant CAV (stenosis >/=50%), showed mean weighted sensitivities of 97% and 94%, specificitie

240 gnostic accuracy significantly improved to a mean weighted sensitivity and specificity of 100% and 99

241 alysis of 64-slice CCTA versus IVUS showed a mean weighted sensitivity and specificity of 81% and 75%

242 ies provided data, permitting computation of mean-weighted sex differences in prevalence.

243 Cs were 47.6% lighter than the standard TCs (mean weight +/- standard deviation, 133 g +/- 14 vs 254

244 Mean weighted TEE was lowest among gastrointestinal (178

245 e of the height in meters) was 36.3, and the mean weight was 102.7 kg (225.9 lb).

246 ters) for all participants was 36.6, and the mean weight was 103.8 kg.

247 e of the patients was 45.1+/-12.0 years, the mean weight was 106.2+/-21.4 kg, and the mean BMI was 38

248 Mean weight was 117 +/- 23 kg (body mass index 48.3 +/-

249 Mean weight was 118 (range, 90-150) kg.

250 , mean BMI was 53.5 (95% CI, 52.9-54.0), and mean weight was 158.8 kg (95% CI, 155.3-162.3 kg).

251 y was 10.1+/-10.7 days (median, 8 days), and mean weight was 2.2+/-0.3 kg (median, 2.2 kg).

252 age at operation was 1.2 days (+/-1.1), the mean weight was 2.6 kg (+/-0.5), the mean operative time

253 Their mean weight was 20 kg.

254 Mean spleen size was 14 cm and mean weight was 263 g.

255 an age at repair was 16 +/- 13 days, and the mean weight was 3.2 +/- 0.7 kg.

256 , the age range was 1 month to 28 years, and mean weight was 37.7 kg +/- 33.1, with a range of 3.4-14

257 13.4 months (+/-8.7), 49% were male, and the mean weight was 6.2 kg (+/-1.3).

258 5.9 +/- 16.1 y for the whole population; the mean weight was 61.4 +/- 10.7 and 58.1 +/- 12.1 kg and b

259 se group) and the control group, whereas the mean weight was remarkably low in patients with chronic

260 Mean weight z scores at discharge were -0.87 (95% CI, -1

261 a significant lower weight at diagnosis (the mean weight z-score had negative values) versus the gene

262 termediate bilirubin concentrations and poor mean weight z-scores 3 months after HPE was also associa

263 Mean weight z-scores were significantly lower by 6 month